ECKERT+ZIEGLERINH O.N.
2.0200
EUR
(+10.38%)
04/17/2025 - 15:34
Holiday 15 min delayed data - Germany Stocks
| Open: | 1.9600 |
| Change: | +0.1900 |
| Volume: | 50,383 |
| Low: | 1.9598 |
| High: | 2.0570 |
| High / Low range: | 0.0972 |
| Type: | Stocks |
| Ticker: | EUZ |
| ISIN: | DE0005659700 |
ECKERT+ZIEGLERINH O.N. news, videos and press releases
For more news please use our advanced search feature.
ECKERT+ZIEGLERINH O.N. - More news...
ECKERT+ZIEGLERINH O.N. - More news...
- 04/11/2025 - 08:30 EQS-News: Eckert & Ziegler Proposes Dividend of € 0.50 for FY 2024
- 04/10/2025 - 13:00 EQS-News: Eckert & Ziegler: US Consul Visits Radiopharmaceutical Production in Braunschweig
- 03/27/2025 - 06:45 EQS-News: Eckert & Ziegler: Record year 2024 with new all-time highs
- 03/25/2025 - 08:30 EQS-News: Eckert & Ziegler to Supply Actinium Pharmaceuticals with Ac-225 for Comprehensive Development Activities
- 03/20/2025 - 13:00 EQS-News: Eckert & Ziegler and AtomVie Global Radiopharma Sign a Global Agreement for Lutetium-177 Supply
- 02/27/2025 - 14:00 EQS-News: Eckert & Ziegler Enters Strategic Partnership with Bicycle Therapeutics for Radioisotope Supply and Contract Development and Manufacturing of Bicycle Radio Conjugates
- 02/25/2025 - 08:59 EQS-News: Eckert & Ziegler Ensures Business Continuity After Cyber-Attack
- 02/13/2025 - 08:21 EQS-Adhoc: Eckert & Ziegler Affected by Cyber Attack
- 02/03/2025 - 12:23 EQS-News: Eckert & Ziegler SE: IT Incident Affects Eckert & Ziegler SE's Communication Channels
- 01/27/2025 - 17:55 EQS-Adhoc: Eckert & Ziegler Announces Preliminary Figures for 2024: Significant Increase in Sales and Adjusted EBIT
- 01/14/2025 - 16:03 EQS-Adhoc: Eckert & Ziegler Signs Licence Agreement for Actinium-225 with Chinese Joint Venture
- 01/13/2025 - 09:00 EQS-News: Eckert & Ziegler and GlyTherix Extend Collaboration With Actinium-225 Supply Agreement
- 12/13/2024 - 08:00 EQS-News: Eckert & Ziegler Submits GalliaPharm® for Approval by Japan’s Health Authority MHLW
- 12/05/2024 - 08:30 EQS-News: Eckert & Ziegler and Ariceum Therapeutics Sign Global Supply Agreement for the Development of Next-Generation Radiotherapeutics for Precision Cancer Treatments
- 12/03/2024 - 13:29 EQS-News: Eckert & Ziegler: Changes in the Executive Board and Supervisory Board
- 12/02/2024 - 08:00 EQS-News: Eckert & Ziegler Begins Production of Actinium-225, Paving the Way for GMP-Grade Supply
- 11/27/2024 - 08:00 EQS-News: Eckert & Ziegler Achieves European Approval for Theralugand® - Lutetium-177 Chloride (n.c.a)
- 11/22/2024 - 14:27 EQS-Adhoc: Eckert & Ziegler raises its forecast for the current financial year once again
- 11/14/2024 - 06:45 EQS-News: Eckert & Ziegler Continues on Growth Path with Strong 9-Month Results in 2024
- 11/13/2024 - 07:54 EQS-Adhoc: Eckert & Ziegler and Telix Pharmaceuticals Enter into a Collaboration and Licence Agreement for Actinium-225
- 10/15/2024 - 14:33 EQS-Adhoc: Eckert & Ziegler Again Increases Sales and Earnings in the First Nine Months Compared to Previous Year
- 10/08/2024 - 06:00 EQS-News: Eckert & Ziegler and GlyTherix Sign Agreement for Lutetium-177 Supply
- 10/02/2024 - 09:43 EQS-News: Eckert & Ziegler: Spin-off of Pentixapharm AG Registered with the Commercial Register
- 08/20/2024 - 15:00 EQS-News: Eckert & Ziegler opens new facilities for radiopharmaceutical plant engineering in Dresden
- 08/13/2024 - 07:00 EQS-News: Eckert & Ziegler becomes European contract manufacturer for Telix's innovative Phase III ProstACT GLOBAL study
- 08/09/2024 - 05:45 EQS-News: Eckert & Ziegler Continues Sales and Earnings Growth in the First Half of 2024
- 08/05/2024 - 13:45 EQS-News: Eckert & Ziegler extends GalliaPharm® availability to the entire European Economic Area
- 07/16/2024 - 12:26 EQS-Adhoc: Eckert & Ziegler Again Increases Sales and Earnings Compared to Previous Year. Profit Forecast Raised for 2024.
- 06/26/2024 - 14:27 EQS-News: Annual General Meeting of Eckert & Ziegler SE Approves Split-Off of Pentixapharm AG
- 06/25/2024 - 10:00 EQS-News: Eckert & Ziegler Subsidiary Pentixapharm Receives Encouraging FDA Feedback to Initiate Phase III Trial with PentixaFor as Radiopharmaceutical Diagnostic in Primary Aldosteronism
